| human menstrual blood derived stem cells / Zhejiang University |
ChiCTR2000029606: Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) |
|
|
| Recruiting | N/A | 63 | China | Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations ;Conventional treatment ;Artificial liver therapy+conventional treatment ;Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations+conventional treatment ;Conventional treatment | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Emergency Project of Science Technology Department of Zhejiang Province “Research on Pneumonia Prevention and Treatment Technology of 2019-nCoV Infection | Novel Coronavirus Pneumonia (COVID-19) | | | | |
| suramin / Zhejiang University |
ChiCTR2000030029: A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19) |
|
|
| Not yet recruiting | N/A | 20 | China | Suramin( IV.) | The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, Self-financing | Novel Coronavirus Pneumonia (COVID-19) | | | | |
| NK cells/combined monoclonal antibodies / Zhejiang University |
NCT04662788: Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies |
|
|
| Not yet recruiting | 1 | 36 | RoW | NK cells/Combined Monoclonal Antibodies | Zhejiang University | Hematological Malignancies | 01/24 | 01/27 | | |
| CD19-7×19 CAR-T / Zhejiang University |
CICPD, NCT04381741: CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Enrolling by invitation | 1 | 24 | RoW | CD19-7×19 CAR-T plus PD1 monoclonal antibody | Second Affiliated Hospital, School of Medicine, Zhejiang University | Diffuse Large B-cell Lymphoma | 09/23 | 09/23 | | |
NCT05659628: CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL |
|
|
| Recruiting | 1 | 24 | RoW | CD19-7×19 CAR-T combined with Tislelizumab | Ningbo No. 1 Hospital, Zhejiang University | Diffuse Large B-cell Lymphoma | 12/24 | 12/26 | | |
| OriC321 / Zhejiang University |
NCT05325801: A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma |
|
|
| Not yet recruiting | 1 | 9 | NA | BMCA and GPRC5D dual target CAR-T cells(OriC321) | Zhejiang University | Multiple Myeloma | 03/24 | 03/25 | | |
| OriCAR-017 / Oricell |
NCT06182696: OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM |
|
|
| Recruiting | 1/2 | 83 | RoW | OriCAR-017 | OriCell Therapeutics Co., Ltd. | Relapsed and/or Refractory Multiple Myeloma | 11/26 | 08/28 | | |
NCT06271252: A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study |
|
|
| Recruiting | 1 | 81 | US | OriCAR-017 | OriCell Therapeutics Co., Ltd. | Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Multiple Myeloma | 12/26 | 04/28 | | |
| Active, not recruiting | 1 | 15 | RoW | GPRC5D-CAR-T | Zhejiang University, OriCell Therapeutics Co., Ltd. | Multiple Myeloma | 06/24 | 06/25 | | |
| TCRx_T / TCRx Therap, Zhejiang University |
NCT05447234: TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy |
|
|
| Not yet recruiting | 1 | 50 | NA | Tcrx T cell | Second Affiliated Hospital, School of Medicine, Zhejiang University, TCRx Therapeutics Co.Ltd | Gastric Cancer, Gastroesophageal-junction Cancer | 03/26 | 03/28 | | |
| CD19/BCMA chimeric antigen receptor T cells / Zhejiang University |
ChiCTR2100049920: A clinical study on the safety and effectiveness of CD19/BCMA chimeric antigen receptor T cells in the treatment of auto-antibody-mediated autoimmune diseases and HLA antibody-positive status before allogeneic hematopoietic stem cell transplantation |
|
|
| Recruiting | 1 | 60 | | CAR-T cell therapy | the First Affiliated Hospital, Zhejiang University School of Medicine; the First Affiliated Hospital, Zhejiang University School of Medicine, National Natural Science Foundation of China | autoimmune diseases | | | | |
NCT05030779: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Systemic Lupus Erythematosus, Autoimmune Diseases | 03/22 | 09/22 | | |
NCT05846347: Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 15 | RoW | GC012F injection, CD19-BCMA CAR-T cells | Zhejiang University, Gracell Biotechnology Shanghai Co., Ltd. | CAR-T | 10/23 | 04/25 | | |
NCT05263817: A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis |
|
|
| Recruiting | 1 | 75 | RoW | CD19/BCMA CAR T-cells, CD19/BCMA CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis | 10/24 | 10/24 | | |
NCT05085444: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Scleroderma, Autoimmune Diseases | 10/24 | 10/24 | | |
NCT05085431: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Sjogren's Syndrome, Autoimmune Diseases | 11/24 | 11/24 | | |
NCT05085418: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Immune Nephritis, Autoimmune Diseases, Lupus Nephritis | 11/24 | 11/24 | | |
| ADGRE2 CAR-T / Zhejiang University |
NCT05463640: Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML |
|
|
| Not yet recruiting | 1 | 20 | RoW | ADGRE2 CAR-T | Zhejiang University | AML | 08/24 | 08/25 | | |
ChiCTR2200061646: To evaluate the safety and efficacy of CLL1/CLL1+CD33/CD33/ADGRE2 CAR-T in the treatment of relapsed and refractory acute myeloid leukemia |
|
|
| Not yet recruiting | N/A | 20 | | Single, intravenous infusion of CAR-T cells | The First Affiliated Hospital of Medical College of Zhejiang University; The First Affiliated Hospital of Medical College of Zhejiang University, Guangzhou Bio-gene Technology Co., Ltd | Acute myeloid leukemia | | | | |
| CLL1+CD33 CAR-T / Hedy Group, Zhejiang University |
| Not yet recruiting | 1 | 20 | RoW | CLL1+CD33 CAR-T | Zhejiang University | AML | 08/24 | 08/25 | | |
| CLL1 CAR-T / Hedy Group, Zhejiang University |
| Not yet recruiting | 1 | 20 | RoW | CLL1 CAR-T | Zhejiang University | AML | 08/24 | 08/25 | | |
| Recruiting | 1 | 36 | RoW | CLL1 CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | AML | 11/24 | 11/24 | | |
| CD33 CAR-T / Hedy Group, Zhejiang University |
NCT05473221: Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML |
|
|
| Not yet recruiting | 1 | 20 | RoW | CD33 CAR-T | Zhejiang University | AML | 08/24 | 08/25 | | |
NCT06762132: A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 27 | RoW | CD33 CAR T-cells, CD33 CAR T-cells injection | Zhejiang University, Shanghai YaKe Biotechnology Ltd. | Acute Myeloid Leukemia | 10/27 | 10/27 | | |
| CB CAR-NK019 / Zhejiang University |
NCT04887012: Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL |
|
|
| Recruiting | 1 | 25 | RoW | anti-CD19 CAR-NK, CAR-NK019 | Second Affiliated Hospital, School of Medicine, Zhejiang University | B-cell Non Hodgkin Lymphoma | 05/22 | 05/24 | | |
NCT05472558: Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL |
|
|
| Recruiting | 1 | 48 | RoW | anti-CD19 CAR-NK, CB CAR-NK019 | Second Affiliated Hospital, School of Medicine, Zhejiang University | B-cell Non Hodgkin Lymphoma | 12/25 | 12/26 | | |
NCT06421701: Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 10 | RoW | anti-CD19 CAR-NK cells | Second Affiliated Hospital, School of Medicine, Zhejiang University | Systemic Lupus Erythematosus | 08/25 | 05/26 | | |
NCT06827782: Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/relapsed Central Nervous System Lymphoma |
|
|
| Enrolling by invitation | 1 | 42 | RoW | anti-CD19 CAR-NK cells | Second Affiliated Hospital, School of Medicine, Zhejiang University | Refractory/recurrent Central Nervous System Lymphoma | 12/26 | 12/28 | | |
NCT06614270: Anti-CD19 IL-10 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases |
|
|
| Recruiting | N/A | 15 | RoW | anti-CD19 CAR-NK cells | Second Affiliated Hospital, School of Medicine, Zhejiang University | Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM), Sjogren's Syndrome, Antiphospholipid Syndrome | 01/26 | 01/27 | | |
| CT101a / Shanghai Zeke Biotech, Zhejiang University |
| Terminated | 1 | 3 | RoW | CT101a | Zhejiang University, Shanghai Zeke Biotechnology Co.，Ltd | AML | 08/22 | 04/23 | | |
| dualCAR-NK19/70 / Zhejiang University |
NCT05842707: Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 48 | RoW | dualCAR-NK19/70 cell, CAR-NK cell | Aibin Liang，MD，Ph.D. | Refractory or Relapsed B-cell Non-Hodgkin Lymphoma | 01/28 | 01/29 | | |
NCT05667155: Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1 | 48 | RoW | CB dualCAR-NK19/70 | Second Affiliated Hospital, School of Medicine, Zhejiang University | B-cell Non Hodgkin Lymphoma | 01/25 | 12/25 | | |
